JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Designing Hypothesis of 2-Substituted-N-[4-(1-methyl-4,5-diphenyl-1H-imidazole-2-yl)phenyl] Acetamide Analogs as Anticancer Agents: QSAR Approach
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Designing Hypothesis of 2-Substituted-N-[4-(1-methyl-4,5-diphenyl-1H-imidazole-2-yl)phenyl] Acetamide Analogs as Anticancer Agents: QSAR Approach
Bedadurge, Ajay B.; Shaikh, Anwar R.;
  PDF(new window)
 Abstract
Quantitative structure-activity relationship (QSAR) analysis for recently synthesized imidazole-(benz)azole and imidazole - piperazine derivatives was studied for their anticancer activities against breast (MCF-7) cell lines. The statistically significant 2D-QSAR models (; ; F test = 36.4635; se = 0.1696; se = 0.12212; pred_; pred_ se = 0.4606 and ; ; F test = 31.8737; se = 0.1951; se = 0.2708; pred_; pred_ se = 0.3950) were developed using molecular design suite (VLifeMDS 4.2). The study was performed with 18 compounds (data set) using random selection and manual selection methods used for the division of the data set into training and test set. Multiple linear regression (MLR) methodology with stepwise (SW) forward-backward variable selection method was used for building the QSAR models. The results of the 2D-QSAR models were further compared with 3D-QSAR models generated by kNN-MFA, (k-Nearest Neighbor Molecular Field Analysis) investigating the substitutional requirements for the favorable anticancer activity. The results derived may be useful in further designing novel imidazole-(benz)azole and imidazole-piperazine derivatives against breast (MCF-7) cell lines prior to synthesis.
 Keywords
Imidazole-(benz)azole and imidazole-piperazine;Breast (MCF-7) cell line;Anticancer;Quantitative structure-activity relationship;kNN-MFA;
 Language
English
 Cited by
 References
1.
Krikas, G.; Schulpis, K.; Reclos, G.; Kokotos, G. Clin. Biochem. 1998, 31, 405. crossref(new window)

2.
Waring, M.; Bailly, C. Gene 1994, 149, 69. crossref(new window)

3.
Rehn, C.; Pindur, U. Monatsh. Chem. 1996, 127, 631. crossref(new window)

4.
Baginski, M.; Fogolari, F.; Briggs, J. J. Mol. Biol. 1997, 274, 253. crossref(new window)

5.
Shui, X.; et al. Curr. Med. Chem. 2000, 7, 59. crossref(new window)

6.
Neidle, S. In Cancer Drug Desing and Discovery, 2nd Ed.; Elsevier Inc.: U.S.A., 2008, p 132.

7.
Moore, M.; Hunter, W.; Langlis-D'Estaintot, B.; Kennard, O. J. Mol. Bio. 1989, 206, 693. crossref(new window)

8.
Pindur, U.; Haber, M.; Sattler, K. J. Chem. Educ. 1993, 70, 263. crossref(new window)

9.
Zhigang, L.; Qing, Y.; Xuhong, Q. Bioorg. Med. Chem. Lett. 2005, 15, 3143. crossref(new window)

10.
Claiborne, C.; Liverton, N.; Nguyen, K. Tetrahedron Lett. 1998, 39, 8939. crossref(new window)

11.
Cui, B.; Zheng, B.; He, K.; Zheng, Q. J. Nat. Prod. 2003, 66, 1101. crossref(new window)

12.
Fazeny-Dorner, B.; Veitl, M.; Wenzel, C.; Piribauer, M.; Rossler, K.; Dieckmann, K.; Ungersbock, K.; Marosi, C. Anticancer Drugs. 2003, 14, 437. crossref(new window)

13.
Haluska, P.; Dy, G.; A. Adjei, A. Eur. J. cancer. 2008, 38, 1685.

14.
Kotteas, E.; Alamara, C.; Kiagia, M.; Pantazopoulos, K.; Oufas, A.; Provata, A.; Chapidou, A.; Syrigos, K. N. Anticancer Res. 2008, 28, 529.

15.
Perez-ruixo, J.; Piotrovskij, V.; Zhang, S.; Hayes, S.; DePorre, P.; Zannikos, P. Br. J. Clin, Pharmacol. 2006, 62, 81. crossref(new window)

16.
Krezel, I. Farmaco 1998, 53, 342. crossref(new window)

17.
Kumar, D.; Jacob, M. R.; Reynolds, M. B.; Kerwin, S. M. Bioorg. Med. Chem. 2002, 10, 3997. crossref(new window)

18.
Hose, C.; Hollingshead M.; Sausville E.; Monks A.; Mol. Cancer Ther. 2003, 2, 1265.

19.
Al-Masoudi, A.; Al-Soud, Y.; Al-Salihi, N.; Al-Masoudi, N. Chem. Hetetrocycl. Compd. 2006, 42, 1377. crossref(new window)

20.
Jackman, A.; Kimbell, R.; Aherne, G.; Brunton, L.; Jansen, G.; Stephens, T.; Smith, M.; Wardleworth, J.; Boyle, F. Clin. Cancer Res. 1997, 3, 911.

21.
Nelson, J.; Rose, L.; Benneft, L. Cancer Res. 1977, 37, 182.

22.
Martin, B.; Mann, J.; Sageot, A. J. Chem. Soc. Perkin Trans. 1, 1999, 2455.

23.
Brian, B.; Andrew, M.; Hana, K.; Padmakumari, T.; William, P.; Jack, C. Mol. Pharmacol. 1997, 52, 839. crossref(new window)

24.
Hansch, C.; Kurup, A.; Garg, R.; Gao, H. Chem. Rev. 2001, 101, 619. crossref(new window)

25.
Yusuf, O.; Ilhan, I.; Zerrin, I.; Gulsen, A. Eur. J. Med. Chem. 2010, 45, 3320. crossref(new window)

26.
Golbraikh, A.; Tropsha, A. J. Comput. Aided Mol. Des. 2002, 16, 357. crossref(new window)

27.
VLifeMDS 4.2; Molecular Design Suite; Vlife Sciences Technologies Pvt. Ltd.: Pune, India, 2012. www.vlifesciences.com

28.
Gasteiger, J; Marsili, M. Tetrahedron. 1980, 36, 3219. crossref(new window)

29.
Ajmani, S.; Jhadav, K.; Kulkarni, S. A. J. Chem. Inf. Model. 2006, 46, 24. crossref(new window)